

IBA Notice of Full Year 2023 Results and Conference Call

FY23 results meeting to take place as a hybrid event on Thursday, 21 March 2024 at 3pm CET

Louvain-la-Neuve, Belgium, 26 February 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2023 on Thursday, 21 March 2024 at 7am CET.

Conference Call Information

IBA's management team will host a hybrid event, including a conference call and webcast conducted in English, to present the half year results, followed by a Q&A session.

The conference call will be held on **Thursday, 21 March 2024 at 3pm CET / 2pm GMT / 10am ET / 7am PT** as a Teams webinar and can be accessed online on <u>this link</u>.

If you would like to join by phone only, please dial (Phone conference ID 204 708 166#):

Belgium:	+32 2 890 97 20
UK:	+44 20 3321 5200
NL:	+31 20 708 6901
LU:	+352 27 87 00 02
US:	+1 347-991-7591
FR:	+33 1 70 99 53 51

The presentation will be available on <u>IBA's investor relations</u> website and on <u>https://www.iba-worldwide.com/full-year-results-2023-press-release-and-conference-call</u> shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

For participants who do not have the Teams application installed, please follow the process described in <u>this link</u> to access the conference.

ENDS

Press release | February 26, 2024



IBA | Ion Beam Applications SA Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Brabant-wallon VAT : 0428.750.985 | T +32 10 47 58 11 | F +32 10 47 58 10 info@iba-group.com | iba-worldwide.com



1



About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

CONTACTS

Soumya Chandramouli Chief Financial Officer +32 10 475 890 Investorrelations@iba-group.com

Olivier Lechien Corporate Communication Director +32 10 475 890 communication@iba-group.com

ICR Consilium Amber Fennell, Matthew Neal, Lucy Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com

Press release | February 26, 2024



